Compare Abeona Therapeutics Inc (ABEO) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Abrdn Physical Platinum Shares ETF trades at $14.39. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | PPLT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $25.23 |
52-Week Low | $4.17 | $11.78 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PPLT, the Aberdeen Physical Platinum Shares ETF, trades at $14.83, up 0.75% on the day, amid a bearish technical outlook with moving averages signaling sell pressure. The fund recently executed a 1-for-10 stock split effective May 18, 2026, adjusting share count without altering the underlying asset value. Key financial ratios are unavailable, as the ETF holds physical platinum, not generating traditional corporate earnings or sales.
The outlook for PPLT hinges on platinum price trends, which face headwinds from weaker industrial demand and competition from gold. Recent news highlights platinum's underperformance versus other precious metals, suggesting cautious sentiment. Risks include commodity volatility and economic cycles, while potential upside relies on a sustained rally in platinum markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
